PRŮVODCE odvětvími

AI in Oncology

AI in oncology uses machine learning to help find tumors on scans and slides, estimate risk, plan radiotherapy and organize information for treatment decisions such as tumor board reviews.

Poslechněte si tento návodAI-vyprávěný · ~3 min

Na této stránce3 min čtení
  1. Přehled
  2. Hluboký ponor
  3. Real-World Implementace
  4. The Future of AI in Oncology
  5. Uvedení do praxe
  6. Pokračujte v objevování
  7. Často kladené otázky

Přehled

It matters because cancer care involves huge volumes of images and data, but so far the strongest evidence is for detection and workflow tasks, not for AI choosing which treatment a patient should get.

Hluboký ponor

Oncologists meet AI in three main places: detection, treatment planning and decision support. Detection is the most mature. In mammography, the Swedish MASAI randomized trial, first reported in 2023, found that AI-supported screening detected more cancers than standard double reading while cutting radiologist screen-reading workload by roughly 44 percent. In pathology, the FDA authorized Paige Prostate in 2021 as the first AI product to assist pathologists reading prostate biopsies. Research models can also estimate features such as microsatellite instability directly from routine stained slides, and MIT and Massachusetts General Hospital researchers built Sybil, which predicts future lung cancer risk from a single low-dose CT scan. Treatment planning is quietly widespread. Auto-contouring tools draft outlines of tumors and nearby organs for radiotherapy, a task that can take clinicians hours by hand. Clinicians still review and edit every contour. Treatment selection is where caution is most needed. IBM's Watson for Oncology was marketed to suggest therapies but faced reports of recommendations that disagreed with experts and some that were unsafe, and IBM later sold its Watson Health business. The lesson was that training on a small set of hypothetical cases and one institution's preferences does not produce reliable general advice. Tumor boards, where surgeons, oncologists, radiologists and pathologists discuss cases together, increasingly use software that assembles data and flags matching clinical trials or guideline pathways. Large language models are being tested to summarize records for these meetings, but hallucinated or outdated facts are a serious risk. The main limit of current evidence is that many studies are retrospective, measure accuracy rather than patient outcomes, and come from a few well-resourced centers. Finding more small cancers is only helpful if it improves survival rather than increasing overdiagnosis.

Real-World Implementace

A breast screening program uses AI to triage mammograms so that likely-normal exams need one radiologist while higher-risk exams get two readers, cutting reading workload.

A radiotherapy team uses auto-contouring software to draw first-draft outlines of organs at risk on CT scans, which a dosimetrist and oncologist then check and correct.

A pathology lab uses an AI system to highlight suspicious areas on digitized prostate biopsy slides so the pathologist reviews those regions carefully.

A hospital's tumor board software gathers imaging, pathology, genomics and treatment history into one dashboard before the weekly multidisciplinary meeting.

The Future of AI in Oncology

Near-term growth is most likely in screening, pathology and radiotherapy workflow, where tasks are well defined and results can be checked. Longer follow-up from screening trials will clarify whether extra detections reduce interval cancers and deaths or add overdiagnosis. Multimodal models that combine images, genomics and records are an active research area, but they will need prospective trials before guiding treatment choices. Tumor boards may use AI summaries and trial matching more often, with clinicians verifying sources. Equity is a real concern, since many models are developed at large academic centers whose patients and equipment may not match community hospitals.

Uvedení do praxe

Proč na tom záleží

  • Kontext a pravidla. Kontext odvětví určuje, zda nápady AI přežijí kontakt s realitou.
  • Kontrola kvality. Omezení domény ovlivňují přijatelnou míru chyb a modely dohledu.
  • Volby sestavy. Úspěšné nasazení sladí technické možnosti s předními pracovními postupy.

Pozor na

  • Regulační požadavky mohou zneplatnit jinak silné prototypy.
  • Historická data mohou zakódovat zaujatost, která poškozuje konkrétní komunity.
  • Starší systémy mohou vytvářet úzká místa integrace a skryté náklady.

Další kroky

  1. Zapojte odborníky na doménu od rámování problému až po hodnocení.
  2. Před spuštěním navrhněte auditní záznamy a dokumentaci.
  3. Předčasně ověřte dodržování a bezpečnostní závazky.
  4. Zavádění ve fázích s jasnými kritérii zastavení a vrácení.

Pokračujte v objevování

Newsletter zdarma

Získejte denní přehled o AI

Tři ověřené příběhy ze světa AI každý všední den ráno, psané srozumitelnou angličtinou. Navždy zdarma, bez reklam.

Jeden e-mail každý všední den. Odhlásit se můžete jedním kliknutím. Vaši adresu nikdy neprodáváme ani nesdílíme.

Otestujte se

Take the AI in Oncology quiz

Okamžitá zpětná vazba ke každé odpovědi a sdílitelný certifikát s ověřitelným ID po absolvování kurzu.

Spustit kvíz

Podpořte bezplatnou AI vzdělávání. AI Understanding je nezisková organizace 501(c)(3) — žádné reklamy, žádná platba za přístup, nikdy. Darujte

Často kladené otázky

What is AI in Oncology?

AI in oncology uses machine learning to help find tumors on scans and slides, estimate risk, plan radiotherapy and organize information for treatment decisions such as tumor board reviews. It matters because cancer care involves huge volumes of images and data, but so far the strongest evidence is for detection and workflow tasks, not for AI choosing which treatment a patient should get.

What did the Swedish MASAI trial report about AI-supported mammography screening?

MASAI, a randomized trial first reported in 2023, found higher detection and a large drop in radiologist reading workload compared with standard double reading.

What was the key lesson from IBM's Watson for Oncology?

Reports of recommendations that disagreed with experts, some unsafe, showed the limits of its training approach. IBM later sold the Watson Health business.

Which product did the FDA authorize in 2021 as the first AI to assist pathologists with prostate biopsies?

Paige Prostate highlights suspicious regions on digitized prostate biopsy slides for pathologist review.

What does Sybil, from MIT and Massachusetts General Hospital, predict?

Sybil estimates a person's future lung cancer risk using one low-dose chest CT.

How do most AI systems handle gigapixel whole-slide pathology images?

Slides are too large to process at once, so patches are encoded and combined, often with attention that produces a heatmap of influential regions.